I. Scharrer – författare

The modern rehabilitation medicine is an important part of the comprehensive me- cal attendance of hemophiliacs. The necessary multidisciplinary team of specialists is available in a qualitative high-class rehabilitation hospital. Indispensable is the point that the coordinating medical specialist in Rehabilitation Medicine on site is skilled in the treatment of hemophiliacs. But he doesn't want and he can't replace the patient's hematologist. He is just the coordinator of the comprehensive team in the rehabilitation clinic. I hope I have shown that rehabilitation is an important topic for most patients with hemophilia. References 1. Neuntes Sozialgesetzbuch (SGB IX) - Rehabilitation und Teilhabe behinderter Menschen - vom 19. 6. 2001 (BGBl. I,S. 1046) 2. Kurth A, Kreuz W, Scharrer I: "Die orthopadische Behandlung von muskulo-skelettalen Komplikationen der Hamophilie". Dtsch Arztebl 2002; 99: A 2928-2935 [Heft 44] 3. BAR: Wegweiser - Rehabilitation und Teilhabe behinderter Menschen,11. Auflage,Fra- furt/Main 2001 4. BAR und Sozialpsychologisches Institut (Koln): Teamentwicklung in der Rehabilitation, Franfurt/Main Juni 2000 5.Buzzard B, Beeton K: "Physiotherapy, Management of Haemophilia", Blackwell Science, Oxford 2000 6. Rizzo Battistella L: "Rehabilitation in Haemophilia - options in the developing world", Haemophilia, 1998, 4, 486-490 7. Beeton K S: "Physiotherapie bei erwachsenen Patienten mit Hamophilie". In Rodriguez- Merchan E C,Goddard N J u. Lee C A (Hrsg): Orthopadische Aspekte der Hamophilie,Stork Medien,Bruchsal 2002 (dt. Ubersetzung) 8.

This book contains the contributions to the 34th Hemophilia Symposium, Hamburg 2003. The main topics are HIV infection and epidemiology, management of bleedings in hemophiliacs with inhibitors, orthopedic problems and therapy in hemophiliacs, therapy with protein C and pediatric hemostaseology. The volume is rounded off by numerous free papers and posters on hemophilia, hemophiliacs with inhibitors, thrombophilia and molecular diagnostics.

Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat­ ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re­ quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat­ ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have.

Die j{hrlichen H{mophilie-Symposien befassen sich mit neuen Erkenntnissen aus der Grundlagenforschung und Klinik der H{- mophilie, verwandter angeborener und erworbener Blutungs- krankheiten und thrombophiler Diathesen. Diese Veranstaltun- gen verfolgen das Ziel, unter Mitwirkung kompetenter Modera- toren und Referenten aller involvierten Fachdisziplinen, [rzten und Wissenschaftler aus dem zentraleurop{ischen Raum aktuelle Erkenntnisse und Erfahrungen zu vermitteln und eine stetige Verbesserung der Krankenversorgung zu bewirken. Die Hauptthemen des vorliegenden Bandes sind auf therapiebe- dingte Gef{hrdungendurch Virusinfektionen und nicht-infek- ti|se Nebenwirkungen gerinnungsaktiver Plasmapr{parate ge- richtet. Im Vordergrund stehen dabei H{ufigkeit, Verlauf, Verh}tung und Therapie der HIV-Infektion, H{ufigkeit und Verh}tung der Hepatitis B- und C-Infektion sowie Behand- lungswege der Hemmk|rperh{mophilie. In weiteren Hauptthemen werden angeborene bzw. heredit{re thrombophile Diathesen, insbesondere Protein C- und Antithrombin III-Mangelzust{nde sowie neue, vor allem molekularbiologische Fortschritte in der h{mostaseologischen Diagnostik verhandelt.Den Abschlu~ bildet eine Serie freier Vortr{ge }ber spezielle klinische Probleme bei angeborenenund erworbenen H{mostasest|rungen.

This book contains the contributions to the 30th Hemophilia Symposium, 1999. The main topics are HIV infection, inhibitors in hemophilia, modern treatment of hemophilia, drug-induced thrombophilia and pediatric hemostasiology. The volume is rounded off by numerous free papers and posters on hemophilia and associated topics.

This book contains the contribution to the 37th Hemophilia Symposium, Hamburg 2006. The main topics are epidemiolgy, treatment of inhibitors in hemophiliacs, hemophilic arthropathy and synovitis, relevant hemophilia treatment 2006, and pediatric hemostasiology. The volume is rounded off by numerous free papers and posters on hemophilia, casuistics, and diagnostics.

This book contains the contribution to the 37th Hemophilia Symposium, Hamburg 2006. The main topics are epidemiolgy, treatment of inhibitors in hemophiliacs, hemophilic arthropathy and synovitis, relevant hemophilia treatment 2006, and pediatric hemostasiology. The volume is rounded off by numerous free papers and posters on hemophilia, casuistics, and diagnostics.

This book contains the contributions to the 30th Hemophilia Symposium, 1999. The main topics are HIV infection, inhibitors in hemophilia, modern treatment of hemophilia, drug-induced thrombophilia and pediatric hemostasiology. The volume is rounded off by numerous free papers and posters on hemophilia and associated topics.

Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat­ ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re­ quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat­ ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have.